Literature DB >> 15565110

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.

Elisabeth B Binder1, Daria Salyakina, Peter Lichtner, Gabriele M Wochnik, Marcus Ising, Benno Pütz, Sergi Papiol, Shaun Seaman, Susanne Lucae, Martin A Kohli, Thomas Nickel, Heike E Künzel, Brigitte Fuchs, Matthias Majer, Andrea Pfennig, Nikola Kern, Jürgen Brunner, Sieglinde Modell, Thomas Baghai, Tobias Deiml, Peter Zill, Brigitta Bondy, Rainer Rupprecht, Thomas Messer, Oliver Köhnlein, Heike Dabitz, Tanja Brückl, Nina Müller, Hildegard Pfister, Roselind Lieb, Jakob C Mueller, Elin Lõhmussaar, Tim M Strom, Thomas Bettecken, Thomas Meitinger, Manfred Uhr, Theo Rein, Florian Holsboer, Bertram Muller-Myhsok.   

Abstract

The stress hormone-regulating hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the causality as well as the treatment of depression. To investigate a possible association between genes regulating the HPA axis and response to antidepressants and susceptibility for depression, we genotyped single-nucleotide polymorphisms in eight of these genes in depressed individuals and matched controls. We found significant associations of response to antidepressants and the recurrence of depressive episodes with single-nucleotide polymorphisms in FKBP5, a glucocorticoid receptor-regulating cochaperone of hsp-90, in two independent samples. These single-nucleotide polymorphisms were also associated with increased intracellular FKBP5 protein expression, which triggers adaptive changes in glucocorticoid receptor and, thereby, HPA-axis regulation. Individuals carrying the associated genotypes had less HPA-axis hyperactivity during the depressive episode. We propose that the FKBP5 variant-dependent alterations in HPA-axis regulation could be related to the faster response to antidepressant drug treatment and the increased recurrence of depressive episodes observed in this subgroup of depressed individuals. These findings support a central role of genes regulating the HPA axis in the causality of depression and the mechanism of action of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565110     DOI: 10.1038/ng1479

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  313 in total

Review 1.  Gene-environment interaction in major depression and antidepressant treatment response.

Authors:  Robert Keers; Rudolf Uher
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

2.  [The future of depression research].

Authors:  F Holsboer
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 3.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 4.  Genetics of emotion.

Authors:  Laura Bevilacqua; David Goldman
Journal:  Trends Cogn Sci       Date:  2011-08-10       Impact factor: 20.229

5.  Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virus-infected individuals.

Authors:  Erick T Tatro; Timothy B Nguyen; Chad A Bousman; Eliezer Masliah; Igor Grant; J Hampton Atkinson; Ian P Everall
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

6.  DNA methylation and sex-specific expression of FKBP5 as correlates of one-month bedtime cortisol levels in healthy individuals.

Authors:  Richard S Lee; Pamela B Mahon; Peter P Zandi; Mary E McCaul; Xiaoju Yang; Utsav Bali; Gary S Wand
Journal:  Psychoneuroendocrinology       Date:  2018-07-04       Impact factor: 4.905

Review 7.  Genomic and epigenomic mechanisms of glucocorticoids in the brain.

Authors:  Jason D Gray; Joshua F Kogan; Jordan Marrocco; Bruce S McEwen
Journal:  Nat Rev Endocrinol       Date:  2017-09-01       Impact factor: 43.330

8.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 9.  Mood disorders after TBI.

Authors:  Ricardo E Jorge; David B Arciniegas
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

Review 10.  The role of FKBP5 in mood disorders: action of FKBP5 on steroid hormone receptors leads to questions about its evolutionary importance.

Authors:  John C O'Leary; Bo Zhang; John Koren; Laura Blair; Chad A Dickey
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.